MAPT and Alzheimer disease: Since then, different groups have developed Tau-Keap1-CPP, QC-01–175, and C004019 PROTACs employing Keap1, CRBN, and VHL E3 ligases, respectively, for the targeted degradation of Tau in AD models (Cummings, 2021; Karlawish and Grill, 2021; Wang et al., 2021).